Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ402MR)

This product GTTS-WQ402MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ402MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1921MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ8918MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ10699MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ2156MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALD-518
GTTS-WQ6106MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ2822MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ1524MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ10992MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MCDS0593A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW